Skip to main content
SpringerLink
Log in

Comment on: “Botulinum Toxin in the Management of Children with Cerebral Palsy”

  • Letter to the Editor
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 04 October 2019

The Original Article was published on 01 July 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Multani I, Manji J, Hastings-Ison T, Khot A, Graham K. Botulinum toxin in the management of children with cerebral palsy. Pediatric Drugs. 2019;21(4):261–81.

    Article  Google Scholar 

  2. O’Flaherty SJ, Janakan V, Morrow AM, Scheinberg AM, Waugh MC. Adverse events and health status following botulinum toxin type A injection. Dev Med Child Neurol. 2011;53(2):125–30.

    Article  Google Scholar 

  3. Valentine J, Davidson S, Bear N, Blair E, Ward R, Thornton A, Stannage K, Watson L, Forbes D, Elliot C. Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy: who, when and why do we treat? Disabil Rehabil. 2019. https://doi.org/10.1080/09638288.2019.1644381.

    Article  PubMed  Google Scholar 

  4. Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55(10):885–910.

    Article  Google Scholar 

  5. Copeland L, Edwards P, Thorley M, Donaghey S, Gascoigne-Pees L, Kentish M, et al. Botulinum toxin A for nonambulatory children with cerebral palsy: a double blind randomized controlled trial. J Pediatr. 2014;165(1):140–6.

    Article  CAS  Google Scholar 

  6. Howell K, Selber P, Graham HK, Reddihough D. Botulinum neurotoxin A: an unusual systemic effect. J Paediatric child health. 2007;43(6):499–501.

    Article  Google Scholar 

  7. Swinney CM, Bau K, Burton KLO, O’Flaherty SJ, Bear N, Paget S. Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections. Dev Med Child Neurol. 2018;60(5):498–504.

    Article  Google Scholar 

  8. Langdon K, Blair E, Davidson S, Valentine J. Adverse events following botulinum toxin type A treatment in children with cerebral palsy. Dev Med Child Neurol. 2010;52(10):972–3.

    Article  Google Scholar 

  9. Edwards P, Sakzewski L, Copeland L, Gascoigne-Pees L, McLennan K, Thorley M, et al. Safety of botulinum toxin A for children with nonambulatory cerebral palsy. Pediatrics. 2015;136(5):895–904.

    Article  Google Scholar 

  10. Blackmore AM, Bear N, Blair E, Langdon K, Moshovis L, Steer K, Wilson A. Predicting respiratory hospital admission in young people with cerebral palsy. Arch Dis Child. 2018;103:1119–24.

    Article  Google Scholar 

  11. Williams SA, Reid S, Elliott C, Shipman P, Valentine J. Muscle volume alterations in spastic muscles immediately following botulinum toxin type-A treatment in children with cerebral palsy. Dev Med Child Neurol. 2013;55(9):813–20.

    Article  Google Scholar 

  12. Park ES, Sim E, Rha D-W, Jung S. Architectural changes of the gastrocnemius muscle after botulinum toxin type A injection in children with cerebral palsy. Yonsei Med J. 2014;55(5):1406–12.

    Article  Google Scholar 

  13. Van Campenhout A, Verhaegen A, Pans S, Molenaers G. Botulinum toxin type A injections in the psoas muscle of children with cerebral palsy: muscle atrophy after motor end plate-targeted injections. Res Dev Disabil. 2013;34(3):1052–8.

    Article  Google Scholar 

  14. Barber L. The effects of botulinum toxin injection frequency on calf muscle growth in young children with spastic cerebral palsy: a 12-month prospective study. J Child Orthop. 2013;7(5):425–33.

    Article  Google Scholar 

  15. Alexander C, Elliott C, Valentine J, Stannage K, Bear N, Donnelly CJ, et al. Muscle volume alterations after first botulinum neurotoxin A treatment in children with cerebral palsy: a 6-month prospective cohort study. Dev Med Child Neurol. 2018;60(11):1165–71.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Perth Children’s Hospital, Nedlands, WA, Australia

    Katherine Langdon

  2. Children’s Health Queensland Hospital and Health Service, Brisbane, QLD, Australia

    Lisa Copeland, Priya Edwards, Kate Rodwell, Kim McLennan, Theresa Carroll & Sasaka Bandaranayake

  3. Murdoch Children’s Research Institute, Parkville, Australia

    Adam Scheinberg

  4. Department of Paediatrics, University of Melbourne, Melbourne, Australia

    Adam Scheinberg

  5. The Children’s Hospital at Westmead, Westmead, NSW, Australia

    Mary-Clare Waugh

  6. HNEkidsRehab, Newcastle, NSW, Australia

    Heather Burnett

  7. Royal Children’s Hospital, Parkville, VIC, Australia

    Neil Wimalasundera

  8. Monash Children’s Hospital, Clayton, VIC, Australia

    Sabine Hennel

  9. Starship Child Health, Auckland, New Zealand

    Eewei Lim

  10. Sydney Children’s Hospital Network, Sydney, Australia

    Steve O’Flaherty

Authors
  1. Katherine Langdon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Copeland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Priya Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kate Rodwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kim McLennan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Theresa Carroll
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sasaka Bandaranayake
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Adam Scheinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mary-Clare Waugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Heather Burnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Neil Wimalasundera
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sabine Hennel
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Eewei Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Steve O’Flaherty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine Langdon.

Ethics declarations

Funding

No funding was received for the publication of this letter.

Conflict of interest

Katherine Langdon, Lisa Copeland, Priya Edwards, Kate Rodwell, Kim McLennan, Theresa Carroll, Sasaka Bandaranayake, Adam Scheinberg, Mary-Clare Waugh, Heather Burnett, Neil Wimalasundera, Sabine Hennel, Eewei Lim, and Steve O’Flaherty declare that they have no conflicts of interest relevant to the content of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Langdon, K., Copeland, L., Edwards, P. et al. Comment on: “Botulinum Toxin in the Management of Children with Cerebral Palsy”. Pediatr Drugs 21, 493–495 (2019). https://doi.org/10.1007/s40272-019-00358-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-019-00358-2

Search

Navigation